MyFinsight
Home
Blog
About
Net loss
-$8,923,846
(-66.18%↓ Y/Y)
Income tax expense
(benefit)
-$107,347
(-140.62%↓ Y/Y)
Gross product revenue
$1,708,560
Loss before income
taxes
-$9,031,193
(-76.88%↓ Y/Y)
Revenues
$1,493,788
Gross-to-net adjustments
$214,772
Operating loss
-$8,716,817
(-76.28%↓ Y/Y)
Total other income
(expense), net
-$314,376
Gross profit
$1,001,945
Interest income
$96,848
Cost of revenues
$491,843
Total operating
expenses
$9,718,762
(96.54%↑ Y/Y)
Interest expense
$231,732
(44.15%↑ Y/Y)
Amortization of deferred
financing costs
$179,492
General and
administrative
$4,219,163
(124.25%↑ Y/Y)
Stock-based compensation
general and...
$3,560,791
(67.55%↑ Y/Y)
Amortization of in-process
research and development
$1,720,312
Research and development
$218,496
(-76.71%↓ Y/Y)
Back
Back
Income Statement
CITIUS ONCOLOGY, INC. (CTOR)
CITIUS ONCOLOGY, INC. (CTOR)
source: myfinsight.com